comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 08:52:14 - browse：49

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Wikipedia

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

PBM reform efforts get punted in Congress

Why palliative psychiatry is worth discussing

New documents shed light on MD Anderson Cancer Institute feud

The Harvard botanist who searched for psychedelics in the Amazon

NIH study of ME/CFS points to clear biological hallmarks

hotspot

comprehensive

focus

Bright Health sells Medicare Advantage business to Molina

PBM reform efforts get punted in Congress

How one medical school became remarkably diverse

Alabama hospital puts IVF treatments on hold

Anesthesiologist group: stop taking Ozempic before surgery

Alabama IVF ruling threatens families facing fatal genetic disease

Virginia high school admissions case could be legal follow

With competition flaring, obesity drug hits goal in liver disease study

Peter Hotez and the public health issue of online harassment

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

focus

Community Health Systems hospitals under DOJ investigation

He's a Nobel laureate. Critics say he was misleading on Covid

NIH study of ME/CFS points to clear biological hallmarks

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Why palliative psychiatry is worth discussing

Why palliative psychiatry is worth discussing

focus

Wikipedia

knowledge

entertainment